Estimated half-life of penta-chlorodibenzofuran (PeCDF) and simulation of PeCDF excretion

Manabu Akahane, Shinya Matsumoto, Yoshiyuki Kanagawa, Jumboku Kajiwara, Takashi Todaka, Hironori Hirakawa, Soichi Koike, Masutaka Furue, Tomoaki Imamura

Research output: Contribution to journalArticle

Abstract

The half-life of 2,3,4,7,8-penta-chlorodibenzofuran (PeCDF) in the Yusho patients has been reported to be approximately seven years. In the present study, we estimated the half-life of PeCDF using data from the medical check-ups of more than 300 Yusho patients. We performed linear regression analysis with a binary logarithm of PeCDF blood level in Yusho patients as the dependent variable, and the measurement year as the independent variable. Our results showed that there were many patients who had shown no reduction of their blood PeCDF level for several years. This result contradicts the previously reported half-life period. Therefore, we believe that a more complicated excretion model needs to be established to explain the discrepancy we found. We hypothesized that there might be two mechanisms of PeCDF assimilation in human digestive tract. In the present study, we also used our hypothesis to simulate PeCDF excretion in Yusho patients.

Original languageEnglish
Pages (from-to)172-178
Number of pages7
JournalFukuoka igaku zasshi = Hukuoka acta medica
Volume100
Issue number5
Publication statusPublished - Jan 1 2009
Externally publishedYes

Fingerprint

Rubiaceae
Half-Life
Gastrointestinal Tract
Linear Models
Regression Analysis

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Akahane, M., Matsumoto, S., Kanagawa, Y., Kajiwara, J., Todaka, T., Hirakawa, H., ... Imamura, T. (2009). Estimated half-life of penta-chlorodibenzofuran (PeCDF) and simulation of PeCDF excretion. Fukuoka igaku zasshi = Hukuoka acta medica, 100(5), 172-178.

Estimated half-life of penta-chlorodibenzofuran (PeCDF) and simulation of PeCDF excretion. / Akahane, Manabu; Matsumoto, Shinya; Kanagawa, Yoshiyuki; Kajiwara, Jumboku; Todaka, Takashi; Hirakawa, Hironori; Koike, Soichi; Furue, Masutaka; Imamura, Tomoaki.

In: Fukuoka igaku zasshi = Hukuoka acta medica, Vol. 100, No. 5, 01.01.2009, p. 172-178.

Research output: Contribution to journalArticle

Akahane, M, Matsumoto, S, Kanagawa, Y, Kajiwara, J, Todaka, T, Hirakawa, H, Koike, S, Furue, M & Imamura, T 2009, 'Estimated half-life of penta-chlorodibenzofuran (PeCDF) and simulation of PeCDF excretion', Fukuoka igaku zasshi = Hukuoka acta medica, vol. 100, no. 5, pp. 172-178.
Akahane M, Matsumoto S, Kanagawa Y, Kajiwara J, Todaka T, Hirakawa H et al. Estimated half-life of penta-chlorodibenzofuran (PeCDF) and simulation of PeCDF excretion. Fukuoka igaku zasshi = Hukuoka acta medica. 2009 Jan 1;100(5):172-178.
Akahane, Manabu ; Matsumoto, Shinya ; Kanagawa, Yoshiyuki ; Kajiwara, Jumboku ; Todaka, Takashi ; Hirakawa, Hironori ; Koike, Soichi ; Furue, Masutaka ; Imamura, Tomoaki. / Estimated half-life of penta-chlorodibenzofuran (PeCDF) and simulation of PeCDF excretion. In: Fukuoka igaku zasshi = Hukuoka acta medica. 2009 ; Vol. 100, No. 5. pp. 172-178.
@article{c819cc55ad2d48939954543fa7a9d9b3,
title = "Estimated half-life of penta-chlorodibenzofuran (PeCDF) and simulation of PeCDF excretion",
abstract = "The half-life of 2,3,4,7,8-penta-chlorodibenzofuran (PeCDF) in the Yusho patients has been reported to be approximately seven years. In the present study, we estimated the half-life of PeCDF using data from the medical check-ups of more than 300 Yusho patients. We performed linear regression analysis with a binary logarithm of PeCDF blood level in Yusho patients as the dependent variable, and the measurement year as the independent variable. Our results showed that there were many patients who had shown no reduction of their blood PeCDF level for several years. This result contradicts the previously reported half-life period. Therefore, we believe that a more complicated excretion model needs to be established to explain the discrepancy we found. We hypothesized that there might be two mechanisms of PeCDF assimilation in human digestive tract. In the present study, we also used our hypothesis to simulate PeCDF excretion in Yusho patients.",
author = "Manabu Akahane and Shinya Matsumoto and Yoshiyuki Kanagawa and Jumboku Kajiwara and Takashi Todaka and Hironori Hirakawa and Soichi Koike and Masutaka Furue and Tomoaki Imamura",
year = "2009",
month = "1",
day = "1",
language = "English",
volume = "100",
pages = "172--178",
journal = "Fukuoka Acta Medica",
issn = "0016-254X",
publisher = "福岡医学会",
number = "5",

}

TY - JOUR

T1 - Estimated half-life of penta-chlorodibenzofuran (PeCDF) and simulation of PeCDF excretion

AU - Akahane, Manabu

AU - Matsumoto, Shinya

AU - Kanagawa, Yoshiyuki

AU - Kajiwara, Jumboku

AU - Todaka, Takashi

AU - Hirakawa, Hironori

AU - Koike, Soichi

AU - Furue, Masutaka

AU - Imamura, Tomoaki

PY - 2009/1/1

Y1 - 2009/1/1

N2 - The half-life of 2,3,4,7,8-penta-chlorodibenzofuran (PeCDF) in the Yusho patients has been reported to be approximately seven years. In the present study, we estimated the half-life of PeCDF using data from the medical check-ups of more than 300 Yusho patients. We performed linear regression analysis with a binary logarithm of PeCDF blood level in Yusho patients as the dependent variable, and the measurement year as the independent variable. Our results showed that there were many patients who had shown no reduction of their blood PeCDF level for several years. This result contradicts the previously reported half-life period. Therefore, we believe that a more complicated excretion model needs to be established to explain the discrepancy we found. We hypothesized that there might be two mechanisms of PeCDF assimilation in human digestive tract. In the present study, we also used our hypothesis to simulate PeCDF excretion in Yusho patients.

AB - The half-life of 2,3,4,7,8-penta-chlorodibenzofuran (PeCDF) in the Yusho patients has been reported to be approximately seven years. In the present study, we estimated the half-life of PeCDF using data from the medical check-ups of more than 300 Yusho patients. We performed linear regression analysis with a binary logarithm of PeCDF blood level in Yusho patients as the dependent variable, and the measurement year as the independent variable. Our results showed that there were many patients who had shown no reduction of their blood PeCDF level for several years. This result contradicts the previously reported half-life period. Therefore, we believe that a more complicated excretion model needs to be established to explain the discrepancy we found. We hypothesized that there might be two mechanisms of PeCDF assimilation in human digestive tract. In the present study, we also used our hypothesis to simulate PeCDF excretion in Yusho patients.

UR - http://www.scopus.com/inward/record.url?scp=68949118374&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68949118374&partnerID=8YFLogxK

M3 - Article

VL - 100

SP - 172

EP - 178

JO - Fukuoka Acta Medica

JF - Fukuoka Acta Medica

SN - 0016-254X

IS - 5

ER -